Cargando…

A narrative review about CDK4/6 inhibitors in the setting of drug resistance: updates on biomarkers and therapeutic strategies in breast cancer

BACKGROUND AND OBJECTIVE: Previous studies have demonstrated that cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy are able to effectively improve the prognosis of hormone receptor positive (HR(+)), human epidermal growth factor receptor 2 (HER2) negative advanced brea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Shidi, Zhang, Haochen, Yang, Na, Yang, Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331716/ https://www.ncbi.nlm.nih.gov/pubmed/37434680 http://dx.doi.org/10.21037/tcr-22-2807

Ejemplares similares

Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib
por: Zhu, Lin, et al.
Publicado: (2022)

CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
por: Sun, Ran, et al.
Publicado: (2022)

CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
por: Yang, Yilan, et al.
Publicado: (2020)

Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2019)

Development of CDK4/6 Inhibitors: A Five Years Update
por: Ammazzalorso, Alessandra, et al.
Publicado: (2021)

Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer
por: Kase, Adam M, et al.
Publicado: (2020)

Determinants of response to CDK4/6 inhibitors in the real-world setting
por: Witkiewicz, Agnieszka K., et al.
Publicado: (2023)

The Therapeutic Potential of CDK4/6 Inhibitors, Novel Cancer Drugs, in Kidney Diseases
por: Liang, Xuan-Bing, et al.
Publicado: (2023)

Senescence as a therapeutically relevant response to CDK4/6 inhibitors
por: Wagner, Verena, et al.
Publicado: (2020)

Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer
por: Wu, Yanmei, et al.
Publicado: (2020)

CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review)
por: Huang, Jinyao, et al.
Publicado: (2022)

Development of CDK inhibitors as cancer therapeutics
por: Lane, D
Publicado: (2005)

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020)

Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
por: Wu, Xuewei, et al.
Publicado: (2021)

Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting
por: Skafida, Efthymia, et al.
Publicado: (2023)

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice
por: McCartney, Amelia, et al.
Publicado: (2019)

Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC
por: Zhang, Jinmeng, et al.
Publicado: (2021)

CDK 4/6 inhibitors for the treatment of meningioma
por: Young, Jacob S., et al.
Publicado: (2022)

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
por: Yang, C, et al.
Publicado: (2017)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

Potential through simplicity: thymidine kinase-1 as a biomarker for CDK4/6 inhibitors
por: McCartney, Amelia, et al.
Publicado: (2020)

CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer
por: Saleh, Lubaid, et al.
Publicado: (2021)

CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer
por: Pan, Qi, et al.
Publicado: (2017)

Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs
por: Yuan, Kai, et al.
Publicado: (2021)

COVID-19 and Pregnancy: An Updated Review about Evidence-Based Therapeutic Strategies
por: Favilli, Alessandro, et al.
Publicado: (2023)

A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas
por: Hadjadj, Djihad, et al.
Publicado: (2017)

CDK4/6 inhibitor: from quiescence to senescence
por: Yoshida, Akihiro, et al.
Publicado: (2015)

Rational drug combinations with CDK4/6 inhibitors in acute lymphoblastic leukemia
por: Bride, Karen L., et al.
Publicado: (2021)

CDK7 inhibitors as anticancer drugs
por: Sava, Georgina P., et al.
Publicado: (2020)

Inhibition of CDK9 as a therapeutic strategy for inflammatory arthritis
por: Hellvard, Annelie, et al.
Publicado: (2016)

Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer
por: Dang, Fabin, et al.
Publicado: (2021)

Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells
por: Buzzetti, Marta, et al.
Publicado: (2021)

CDK9 inhibition strategy defines distinct sets of target genes
por: Garriga, Judit, et al.
Publicado: (2014)

Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity
por: Chen, Zhenghu, et al.
Publicado: (2016)

CDK4/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity – a narrative review
por: Pavlovic, Dragica, et al.
Publicado: (2023)

The interplay of CDK4 and CDK6 in melanoma
por: Kollmann, Karoline, et al.
Publicado: (2019)

Expression of CDK6 in Stomach Cancer and the Effect of CDK4/6 Inhibitor PD-0332991 on the Function of Stomach Cancer Cells
por: Liu, Yu, et al.
Publicado: (2022)

Unraveling the genomic determinants of response to CDK4/6 inhibitors
por: Litchfield, Lacey M., et al.
Publicado: (2018)

The role of CDK4/6 inhibitors in early breast cancer
por: Gil-Gil, Miguel, et al.
Publicado: (2021)

Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
por: van Aken, Evert S. M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_496b3m40opto2kt5ddms2jj3rr